BlackBerry Shares Surge Despite Leading Report with Non-GAAP Financials

Published on: 20 Dec, 2019

BlackBerry (NYSE: BB) reported its third quarter financial results on Friday morning. The Company topped analysts’ earnings and revenue estimates, which sent shares higher by 10% late morning.

For the quarter, BlackBerry reported non-GAAP earnings of USD 0.03 per share on non-GAAP revenues of USD 280 Million. Analysts anticipated earnings of USD 0.01 per share on revenues of USD 271.9 Million.

While BlackBerry surpassed revenue estimates, the Company’s GAAP revenues missed expectations.

BlackBerry started its quarterly financial press release stating its non-GAAP metrics for the quarter, which is a practice normally shunned by the Securities and Exchange Commission, according to MarketWatch.

The Company reported that its non-GAAP revenue rose by 23% year-over-year, while GAAP revenues increased by 18% year-over-year.

Total non-GAAP software and services revenue was USD 275 Million, up 26% year-over-year. Third quarter recurring software and services revenue was over 90%.

At the end of the quarter, BlackBerry’s North America segment reported total revenues of USD 188 Million, accounting for 70.4% of its total revenues. In comparison, BlackBerry’s North American market only accounted for 66.8% of total revenues.

Meanwhile, BlackBerry’s Europe, Middle East and Africa saw its revenue share dwindle. The segment delivered revenues of USD 60 Million, accounting for 22.5% compared to 24.8% in the same period last year. BlackBerry’s other regions segment remained unchanged in terms of growth, however, its revenue share decreased from 8.4% to 7.1%.

“BlackBerry achieved sequential growth in revenue across all of our software businesses while generating healthy non-GAAP profitability and free cash flow as we continue to invest in our future,” said John Chen, Executive Chairman and Chief Executive Officer, BlackBerry. “I am pleased with our progress. Our pipeline is growing as we deliver against our product roadmap and execute on our go-to-market expansion.”


  • 2123Views
  • 10Comments

Recommend to Friends

  • facebook
  • Twitter
  • google plus
  • pinterest
  • Digg
  • stumbleupon
  • Reddit
  • linkedin

Bryan Shin



Sign Up for Weekly Updates

Opt-into our eNewsletter NOW! For the Latest Trending Financial News Topics in Cannabis, Tech, Biotechs, Precious Metals, Energy, Renewable Energy and much more!

Related Posts

14 Jul, 2017 3231
19 Jul, 2017 3098
28 Aug, 2017 2998
02 Nov, 2017 3355



Jun 29, 2020 at 10 13 am

achat levitra - cialis pills cialis shrink prostate cialis prices achat levitra 10 mg orodispersible


cialis 5 mg

Jul 22, 2020 at 05 24 pm

Keflex Expansion Joint accurffrut - Cialis Viancy free sample of cialis pill fortiods Cialis MoreKeli Cialis 5 Mg Quanto Costa


buy cialis professional

Aug 22, 2020 at 07 38 pm

cialis side effects neuroses Optineeswepe - order cialis Envivy Doryx Website Discount On Line Oraphy cialis price geadly Cephalexin Ingredients


cialis 40 mg

Sep 17, 2020 at 06 57 am

Topamax Optineeswepe - Cialis Envivy viagra generico sicuro Oraphy Cialis geadly Viagra O Cialis Cual Es Mejor



May 31, 2021 at 08 40 am

buy cialis online with a prescription



Jun 16, 2021 at 09 59 pm

buy cialis non prescription



Jul 02, 2021 at 07 59 am

reliable source for dapoxetine



Jul 20, 2021 at 03 08 pm

buy antabuse



Aug 07, 2021 at 04 55 pm

best price for generic cialis



Oct 13, 2023 at 07 17 pm

buy cialis canadian They have the same chemical properties but, on treatment of rat hepatocytes in culture, R alpha hydroxytamoxifen gave at least eight times as many DNA adducts as the S isomer